Last edition
News about "Merck to Acquire Cidara Therapeutics"
Merck Poised to Acquire Cidara Therapeutics in Deal Valued Above USD 3.3 Billion
Merck & Co. is reportedly closing in on the acquisition of Cidara Therapeutics, a biotechnology company focused on long-acting antibody treatments for influenza. The deal is expected to value Cidara above its USD 3.3 billion market capitalisation.
Merck To Acquire Cidara Therapeutics | 14/11/2025 | By Darshana
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members